Growth Metrics

Zymeworks (ZYME) Liabilities and Shareholders Equity (2021 - 2025)

Zymeworks' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $556.4 million for Q3 2023.

  • For Q3 2023, Liabilities and Shareholders Equity rose 85.29% year-over-year to $556.4 million; the TTM value through Dec 2023 reached $1.8 billion, up 85.37%, while the annual FY2022 figure was $648.7 million, 66.71% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2023 was $556.4 million at Zymeworks, down from $602.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $648.7 million in Q4 2022 and bottomed at $300.3 million in Q3 2022.
  • The 3-year median for Liabilities and Shareholders Equity is $578.6 million (2023), against an average of $516.2 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 66.71% in 2022 before it skyrocketed 85.29% in 2023.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $389.1 million in 2021, then surged by 66.71% to $648.7 million in 2022, then dropped by 14.24% to $556.4 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Liabilities and Shareholders Equity are $556.4 million (Q3 2023), $602.1 million (Q2 2023), and $600.7 million (Q1 2023).